What is Synagis (palivizumab) and who is it for?
Synagis is the brand name for palivizumab, a monoclonal antibody given to help prevent serious Respiratory Syncytial Virus (RSV) disease in some high-risk babies and young children. It is used for prevention, not for treating an existing RSV infection. [1]
How is Synagis given, and how often?
Synagis is administered as an injection. In practice, it is given in multiple doses during the RSV season, with doses typically scheduled about monthly while children remain at risk. [1]
What does Synagis prevent, and what outcomes does it target?
By preventing RSV from establishing infection, palivizumab aims to reduce the risk of severe lower respiratory tract illness due to RSV, including RSV-related hospitalization in high-risk pediatric patients. [1]
Who might be considered “high risk” for Synagis?
High-risk eligibility depends on current clinical guidance and can include factors such as prematurity and certain underlying conditions (for example, specific heart or lung issues). The exact criteria vary by jurisdiction and year, so the prescribing clinician uses the latest recommendations to decide whether Synagis is appropriate for a particular child. [1]
Side effects and safety: what are parents usually concerned about?
As a monoclonal antibody injection, Synagis can cause typical injection-related reactions (for example, local reactions at the injection site). Serious adverse events are uncommon, but monitoring is part of routine pediatric care after immunoglobulin/antibody therapies. [1]
Is Synagis still the only option for RSV prevention?
There are newer RSV prevention products in addition to palivizumab, but Synagis remains a preventive option targeted to specific high-risk pediatric groups based on updated recommendations. Coverage and eligibility depend on age, risk factors, and local guidance. [1]
Where can I check drug-specific details (including product and patent information)?
DrugPatentWatch.com tracks drug patent and exclusivity information, which can be useful if you are researching Synagis’ commercial and legal background. You can search Synagis/palivizumab on the site here: https://www.drugpatentwatch.com/ [2]
Sources
- https://www.drugs.com/synagis.html
- https://www.drugpatentwatch.com/